Get the Stockscreener App
191.75
1.04%
-2.01
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Becton Dickinson Co stock is traded at $191.75, with a volume of 1.41M.
It is down -1.04% in the last 24 hours and up +5.44% over the past month.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
See More
Previous Close:
$193.76
Open:
$194.42
24h Volume:
1.41M
Relative Volume:
0.88
Market Cap:
$52.23B
Revenue:
$21.37B
Net Income/Loss:
$1.41B
P/E Ratio:
48.62
EPS:
3.9437
Net Cash Flow:
$3.07B
1W Performance:
+4.35%
1M Performance:
+5.44%
6M Performance:
+23.85%
1Y Performance:
+3.50%
1-Day Range:
$190.21
$195.99
1-Week Range:
$184.32
$195.99
52-Week Range:
$140.11
$213.08
Becton Dickinson Co Stock (BDX) Company Profile
Name
Becton Dickinson Co
Sector
Industry
Phone
(201) 847-6800
Address
ONE BECTON DR, FRANKLIN LAKES
Compare BDX vs ISRG, RMD, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDX
Becton Dickinson Co
|
191.75 | 52.23B | 21.37B | 1.41B | 3.07B | 3.9437 |
ISRG
Intuitive Surgical Inc
|
426.70 | 150.74B | 11.03B | 3.16B | 3.22B | 8.7251 |
RMD
Resmed Inc
|
238.97 | 33.61B | 5.54B | 1.52B | 1.74B | 10.37 |
ALC
Alcon Inc
|
66.18 | 31.99B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
35.96 | 31.55B | 29.14B | 1.07B | 1.05B | 1.1956 |
Becton Dickinson Co Stock (BDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-28-26 | Initiated | UBS | Buy |
| May-04-26 | Resumed | Evercore ISI | Outperform |
| Apr-10-26 | Resumed | Goldman | Neutral |
| Feb-10-26 | Resumed | Barclays | Overweight |
| Feb-03-26 | Resumed | Citigroup | Buy |
| Sep-25-25 | Initiated | RBC Capital Mkts | Sector Perform |
| May-22-25 | Downgrade | Citigroup | Buy → Neutral |
| May-02-25 | Downgrade | Goldman | Buy → Neutral |
| May-02-25 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-02-25 | Downgrade | Raymond James | Outperform → Mkt Perform |
| May-01-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-01-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| May-01-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-01-24 | Upgrade | Citigroup | Neutral → Buy |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-24-23 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-30-23 | Resumed | Morgan Stanley | Overweight |
| May-05-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-12-23 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Jan-03-23 | Upgrade | BofA Securities | Neutral → Buy |
| Dec-12-22 | Upgrade | Citigroup | Sell → Neutral |
| Jul-11-22 | Downgrade | Citigroup | Neutral → Sell |
| Jun-24-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-18-22 | Resumed | Raymond James | Mkt Perform |
| Mar-02-22 | Resumed | BofA Securities | Neutral |
| Dec-08-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-25-21 | Initiated | Barclays | Equal Weight |
| Dec-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-15-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-09-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-01-20 | Resumed | Goldman | Buy |
| Mar-05-20 | Initiated | Citigroup | Neutral |
| Feb-07-20 | Downgrade | Cowen | Outperform → Market Perform |
| Feb-07-20 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Feb-07-20 | Downgrade | Raymond James | Strong Buy → Outperform |
| Feb-06-20 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-08-20 | Downgrade | Barclays | Overweight → Equal Weight |
| May-13-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-07-18 | Initiated | Deutsche Bank | Buy |
| Oct-16-18 | Initiated | Barclays | Equal Weight |
| Jun-21-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Jan-19-18 | Resumed | BofA/Merrill | Buy |
| Jan-05-18 | Upgrade | Citigroup | Sell → Neutral |
| Jan-05-18 | Initiated | KeyBanc Capital Mkts | Overweight |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Dec-29-17 | Reiterated | Deutsche Bank | Buy |
View All
Becton Dickinson Co Stock (BDX) Latest News
BD's Revello Stent Shows Strong AGILITY Trial Results for PAD Patients - Zacks Investment Research
Global Microbiology Testing Market to Grow Rapidly at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
Will Becton Dickinson (BDX) Beat Estimates Again in Its Next Earnings Report? - Zacks Investment Research
News | Medical-supply maker BD pledges $19 billion investment in US operations - CoStar
Becton Dickinson & Co. stock outperforms competitors on strong trading day - MarketWatch
Celebrating a medical milestone - Plastics News
BD strikes $19B manufacturing deal with US government - NJBIZ
Barclays Initiates Coverage on Becton, Dickinson and Company With Underweight Rating, $165 Price Target - Moomoo
BDX Expands U.S. Manufacturing With $19B Healthcare Investment - Zacks Investment Research
Becton, Dickinson and Company (BDX) Stock Forecast and Price Target 2026 $BDX - MarketBeat
Becton Dickinson pledges $19 billion US investment in deal with government - Reuters
Becton Dickinson to Spend $3 Billion Expanding US Medical Manufacturing, Trump Says - BigGo Finance
BD to invest billions in U.S. manufacturing - Medical Design & Outsourcing
Becton Dickinson Commits Massive $19 Billion To Expand Domestic Medical Manufacturing - Benzinga
BD to invest $19B in the US to bring relief from future tariffs - BioWorld News
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing By Investing.com - Investing.com
Becton Dickinson to Invest $19 Billion in U.S. in Exchange for Tariff Relief - WSJ
BD Appoints Ferass Abuzaina as Worldwide President of Surgery – Company Announcement - Financial Times
A new leader takes charge of BD’s Surgery business immediately - Stock Titan
Becton Dickinson to invest $19 billion in US - Yahoo Finance
BD and U.S. Government Launch Landmark Partnership to Expand U.S. Manufacturing and Strengthen America's Healthcare Resilience – Company AnnouncementFT.com - Financial Times
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs L - Benzinga
Trump Says Becton Dickinson to Invest $3 Billion in US Manufacturing as 'Strong' Medical Device Tariffs Loom by Year-End - TradingView
Trump Says Becton Dickinson to Invest $3 Billion to Expand Medical Product Manufacturing - NTD News
Becton Dickinson (BDX) to Invest $3 Billion in U.S. Medical Supp - GuruFocus
Trump says Becton Dickinson to invest $3 billion in US medical manufacturing - Yahoo Finance
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing - Reuters
Trump says Becton Dickinson to invest $3 billion to expand US medical product manufacturing - Yahoo Finance Singapore
Becton Dickinson & Co (XBUL:BOX) Stock Forecast, Price Targets and Analysts Predictions - GuruFocus
Becton Dickinson & Co. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Becton, Dickinson and Company (BDX) Stock Forecasts - Yahoo Finance
Becton Dickinson Q3 2026 Earnings Call: Complete Transcript - Benzinga
Becton, Dickinson and Company (BDX) Stock forecasts - Yahoo Finance Australia
XS276302639 Bond Profile: Coupon and Redemption - TradingView
RBC Capital Maintains Becton Dickinson & Co(BDX.US) With Hold Rating, Maintains Target Price $190 - Moomoo
Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex - Zacks Investment Research
Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex - Yahoo Finance
Becton, Dickinson and Company (BDX) Stock Forecasts - Yahoo Finance
Global Liver Cancer Diagnostics Market to Observe Impressive Growth at a CAGR of ~9% by 2034 | DelveInsight - GlobeNewswire Inc.
5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve - Zacks Investment Research
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co. stock outperforms competitors despite losses on the day - MarketWatch
Becton Dickinson & Co (BDX) Insider Sale: EVP, Chief Revenue Off - GuruFocus
BDX.GE Bond Profile: Coupon and Redemption - tradingview.com
Form 4 Becton Dickinson and Co For: 29 September By Investing.com - Investing.com Nigeria
Becton Dickinson EVP Michael Feld sells $13,961 in BDX shares - Investing.com
An executive at Becton Dickinson (BDX) sells 76 shares at $183.70 each. - Stock Titan
Becton Dickinson & Co. stock underperforms Tuesday when compared to competitors - MarketWatch
ETFs Investing in Becton, Dickinson and Company Stocks - tradingview.com
More than $100 million went into a Utah medical-device plant, now marking 70 years in Sandy. - Stock Titan
Becton Dickinson Co Stock (BDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Becton Dickinson Co Stock (BDX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MICHAEL FELD | Officer |
Sep 28 '26 |
Proposed Sale |
183.82 |
76 |
13,970 |
0 |
| MICHAEL FELD | Officer |
Aug 26 '26 |
Proposed Sale |
189.78 |
165 |
31,314 |
0 |
| Feld Michael | EVP, Chief Revenue Officer |
Aug 26 '26 |
Sale |
188.49 |
165 |
31,101 |
19,720 |
| RICHARD BYRD | Former Officer |
Aug 20 '26 |
Proposed Sale |
187.97 |
1,330 |
249,993 |
0 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Sale |
185.00 |
4,152 |
768,120 |
110,163 |
| Polen Thomas E Jr | Chairman, CEO and President |
Aug 13 '26 |
Option Exercise |
167.25 |
43,278 |
7,238,246 |
153,441 |
| THOMAS POLEN | Director |
Aug 13 '26 |
Proposed Sale |
183.58 |
4,152 |
762,224 |
0 |
| Roland Goette | Officer |
Aug 11 '26 |
Proposed Sale |
180.84 |
2,438 |
440,877 |
0 |
| Goette Roland | EVP and President, EMEA |
Aug 11 '26 |
Sale |
180.84 |
2,438 |
440,888 |
14,856 |
| SHANA NEAL | Officer |
Aug 03 '26 |
Proposed Sale |
165.62 |
1,500 |
248,430 |
0 |
1.35%
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):